Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Value of Prescription Drugs Value Based Agreements (VBAs)- PAVE Act Biosimilars Rebate Reform Pricing Transparency: SPIKE Act, HR 2069 and STAR Act, HR 2113 Oncology Care Model - CMS Personalized Medicine H.R. 6, SUPPORT for Patients and Communities Act -House & Senate
Prescription Drug STAR Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Value of Prescription Drugs Value Based Agreements (VBAs)- PAVE Act Biosimilars Rebate Reform Pricing Transparency: SPIKE Act, HR 2069 and STAR Act, HR 2113 Oncology Care Model - CMS Personalized Medicine H.R. 6, SUPPORT for Patients and Communities Act -House & Senate
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2019 · second_quarter · 2A
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicare Part B Intl. Pricing Index ANPRM
FDA Patent Settlement legislation Intellectual property and patent issues
Source: Senate LDA
SUPPORT for Patients and Communities Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Value of Prescription Drugs Value Based Agreements (VBAs)- PAVE Act Biosimilars Rebate Reform Pricing Transparency: SPIKE Act, HR 2069 and STAR Act, HR 2113 Oncology Care Model - CMS Personalized Medicine H.R. 6, SUPPORT for Patients and Communities Act -House & Senate
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Vaccines for Children program
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Innovative Payments Vaccines for Children program
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Medicare Telehealth Parity Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Medicare Telehealth Parity Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Medicare Telehealth Parity Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Medicare Telehealth Parity Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Medicare Telehealth Parity Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
Medicare Telehealth Parity Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Standardizing Electronic Prior Authorization for Safe Prescribing Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Preventing Addiction for Susceptible Seniors Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Preventing Addiction for Susceptible Seniors Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Preventing Addiction for Susceptible Seniors Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Preventing Addiction for Susceptible Seniors Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Preventing Addiction for Susceptible Seniors Act of 2018
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Protecting Medicare from Executive Action Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Protecting Medicare from Executive Action Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Protecting Medicare from Executive Action Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Protecting Medicare from Executive Action Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
Protecting Medicare from Executive Action Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Protecting Medicare from Executive Action Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Cancer Care Payment Reform Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Vaccines for Children program
Cancer Care Payment Reform Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Innovative Payments Vaccines for Children program
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Vaccines for Children program
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Innovative Payments Vaccines for Children program
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Vaccines for Children program
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Innovative Payments Vaccines for Children program
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
American Health Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Medicare Telehealth Parity Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
Protecting Medicare from Executive Action Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
Cancer Care Payment Reform Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Cancer Care Payment Reform Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Affordable and Safe Prescription Drug Importation Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
Cancer Care Payment Reform Act of 2016
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Cancer Care Payment Reform Act of 2016
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Antimicrobial resistance issues and S. 185, The PATH Act.
Antimicrobial resistance issues and S. 185, The PATH Act.
MODDERN Cures Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
HR 3116 (MODDERN Cures Act) issues related to data exclusivity and patent rights for dormant therapies
MODDERN Cures Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Issues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures HR 3116 (MODDERN Cures Act) issues related to data exclusivity and patent rights for dormant therapies Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing programIssues related to pediatric medication access and impact of public guidelines on access Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number) Issues related to oncology legislation, including medication affordability Issues related to opiod use, diversion and DEA scheduling (no legislation) Issues related to transition of care from different care sites (no legislation) Issues related to drug safety and supply chain protections, including e-labeling (no bill number)
Antibiotic Development to Advance Patient Treatment Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 3742 - Legislative proposals regarding the development and reimbursement of antibiotics Infant repiratory health issues - no legislation assigned
Patent Abuse Reduction Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform
Patent Litigation Integrity Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform
Patent Transparency and Improvements Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities
Patent Transparency and Improvements Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities
Patent Transparency and Improvements Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S 1720 - patent litigation reform; Issues related to intellectual property practices in foreign countries and impact on US entities
Patent Transparency and Improvements Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform
Patent Transparency and Improvements Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S1720 - patent litigation reform. Issues Related to intellectual property practices in foreign countries and impact on US entities.
Patent Transparency and Improvements Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities
REPEAL HIV Discrimination Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
REPEAL HIV Discrimination Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform incluiding issues related to the Part D program and those related to low income beneficiaries and protected medication classes.
REPEAL HIV Discrimination Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
REPEAL HIV Discrimination Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
REPEAL HIV Discrimination Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
REPEAL HIV Discrimination Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform incluiding issues related to the Part D program and those related to low income beneficiaries and protected medication classes.
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Indonesian Family Refugee Protection Act
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Medicare Drug Savings Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
Medicare Drug Savings Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
Medicare Drug Savings Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
Medicare Drug Savings Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
Safeguarding America's Pharmaceuticals Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R. 1919, H.R. 3204, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections
Safeguarding America's Pharmaceuticals Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 1919, H.R. 3204, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections Legislative proposals regarding the development of antibiotics (no assigned legislation) H.R. 2725, S. 1413 - FDA user feesH.R. 3116 - MODDERN Cures Act - legislation to provide patent incentives for the development of innovative diagnostic tests therapies Federal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration HR 2985 - regarding the development of new combination drugs
Safeguarding America's Pharmaceuticals Act of 2013
Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP
H.R.1919, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections
Medicare Part D coverage and reimbursement Value of Prescription Drugs Prescription Drug Importation Innovative Payment Models Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Value of Prescription Drugs Price Transparency Oncology Care Model Personalized Medicine Value in Healthcare Initiative & ADA/AHA Know Diabetes By Heart Collaborative-Chronic Care Diagnostics
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2019 · second_quarter · Q2
Value of Prescription Drugs Price Transparency Oncology Care Model Personalized Medicine Value in Healthcare Initiative & ADA/AHA Know Diabetes By Heart Collaborative-Chronic Care Diagnostics
FDA Patent Settlement legislation Intellectual property and patent issues
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Changes to the Medicaid Drug Rebate Program (AMP Cap) Medicare Part B Intl. Pricing Index ANPRM
Medicare Part D coverage and reimbursement Value of Prescription Drugs Prescription Drug Importation Innovative Payment Models Price Transparency Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2019 · first_quarter · Q1
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and reimbursement Medicaid Coverage Rebate reform Medicare Part B IPU proposed rule - House Changes to the Medicaid Drug Rebate Program (AMP Cap) - House Medicare Part B Intl. Pricing Index ANPRM - Senate & House & CMS
FDA Patent Settlement legislation - House
Value of Prescription Drugs Value Based Agreements (VBAs)- PAVE Act Biosimilars Rebate Reform Pricing Transparency: SPIKE Act, HR 2069 and STAR Act, HR 2113 Oncology Care Model - CMS Personalized Medicine H.R. 6, SUPPORT for Patients and Communities Act -House & Senate
Medicare coverage Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D & B Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2018 · fourth_quarter · 4A
Compulsory licensing
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2018 · third_quarter · 3A
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2018 · fourth_quarter · Q4
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
Compulsory licensing
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint Drug pricing
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2018 · third_quarter · Q3
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Vaccines for Children program
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2018 · second_quarter · Q2
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Vaccines for Children program
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic prior authorization (ePA) bill (HR 4841)/ H.R. 5773, the Preventing Addiction Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues & drug discount program Presidents Drug Pricing Blueprint
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2018 · first_quarter · Q1
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834) Innovative Payments Vaccines for Children program
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2017 · fourth_quarter · Q4
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Adherence & Medication Synchronization Bill/ SYNC Act - Medication Adherence (House) Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 (Senate S.870) Medicare Telehealth Parity Act (H.R. 2550) Electronic Prior Authorization Under Medicare Part D (House) Cardiac Bundled Payment Model (HHS/CMMI) Medicare Part D coverage and reimbursement Value of Prescription Drugs, Senate & House Prescription Drug Importation, Senate & House Innovative Payment Models, Senate & House Price Transparency, Senate & House S. 251, Senate and House CDC Asthma Funding, Senate Legislative proposals to change Medicare Part D Medicaid and 340B issues
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2017 · third_quarter · Q3
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care (S 870) Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 463, H 1834)
Prescription Drug User Fee Act - implementation and general legislative planning
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2017 · second_quarter · Q2
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and remimbursement Medicaid Coverage
Prescription Drug User Fee Act - implementation and general legislative planning
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2017 · first_quarter · Q1
Prescription Drug User Fee Act - implementation and general legislative planning
American Health Care Act (HR 1628 House) SYNC Act - Medication Adherence (House) STRIKE Act - Senate Value of Prescription Drugs Chronic Care - Druge Adherence and Continuity of Care Price Transparency Oncology Oncology Care Model - CMS Personalized Medicine Affordable and Safe Prescription Drug Importation Act - S 469 Cancer Care Payment Reform Act (S 3211)
Medicare Part D Coverage and Reimbursement Medicare Part D Non-Interference Legislative proposals to change Medicare Part D Medicare Part B coverage and remimbursement Medicaid Coverage
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2016 · fourth_quarter · Q4
21st Century Cures/Innovation Proposal, Senate & House Prescription Drug Access, Senate & House Chronic Care - Drug Adherence and Continuity of Care, House and Senate Value of Prescription Drugs, Senate & House Global Health/Non-Communicable Diseases in Africa - House & Senate
Prescription Drug User Fee Authorization Legislative Planning generally. House and Senate
Medicare Part D coverage and reimbursement. Medicare Part D Low Income Subsidy. Legislative proposals to change Medicare Part D. Medicaid coverage. Medicare Part B proposed demonstration program. House and Senate.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2016 · third_quarter · Q3
21st Century Cures/Innovation Proposal, Senate & House Prescription Drug Access, Senate & House Moonshot Initiative Chronic Care - Drug Adherence and Continuity of Care, House and Senate Value of Prescription Drugs, Senate & House Global Health/Non-Communicable Diseases in Africa - House & Senate
Prescription Drug User Fee Authorization Legislative Planning generally. House and Senate
Medicare Part D coverage and reimbursement. Medicare Part D Low Income Subsidy. Legislative proposals to change Medicare Part D. Medicaid coverage. Medicare Part B proposed demonstration program. House and Senate.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2016 · second_quarter · Q2
Prescription Drug User Fee Authorization Legislative Planning generally. House and Senate
Medicare Part D coverage and reimbursement. Medicare Part D Low Income Subsidy. Legislative proposals to change Medicare Part D. Medicaid coverage. Medicare Part B proposed demonstration program. House and Senate.
Antimicrobial resistance issues and S. 185, The PATH Act.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2016 · first_quarter · Q1
Patent litigation reform. Issues related to intellectual property practices in foreign countries and impact on US entities. Patents - House and Senate.
Prescription Drug User Fee Authorization Legislative Planning generally. House and Senate
Antimicrobial resistance issues and S. 185, The PATH Act.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2015 · fourth_quarter · Q4
Medicare and Medicaid reform including issues related to the Part D program and those related to low income beneficiaries and protected medication classes.
Patent litigation reform. Issues related to intellectual property practices in foreign countries and impact on US entities.
Issues related to 21st Century Cures legislation.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2015 · third_quarter · Q3
Medicare and Medicaid reform including issues related to the Part D program and those related to low income beneficiaries and protected medication classes.
Patent litigation reform. Issues related to intellectual property practices in foreign countries and impact on US entities.
Issues related to 21st Century Cures legislation.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2015 · second_quarter · Q2
Issues related to 21st Century Cures legislation.
Patent litigation reform. Issues related to intellectual property practices in foreign countries and impact on US entities.
Medicare and Medicaid reform including issues related to the Part D program and those related to low income beneficiaries and protected medication classes.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2015 · first_quarter · Q1
Medicare and Medicaid reform including issues related to the Part D program and those related to low income beneficiaries and protected medication classes.
Patent litigation reform. Issues related to intellectual property practices in foreign countries an dimpact on US entities.
Issues related to 21st Century Cures legislation.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2014 · second_quarter · 2A
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
S 1720 - patent litigation reform; Issues related to intellectual property practices in foreign countries and impact on US entities
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program; Issues related to pediatric medication access and impact of public guidelines on access; Issues related to oncology legislation,including medication affordability;Issues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures; Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number) (Jennifer Snow and Christine Bloomquist were deleted from this and the prior amendment to this report because they did not meet the legal definition of lobbyists)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2014 · fourth_quarter · Q4
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform incluiding issues related to the Part D program and those related to low income beneficiaries and protected medication classes.
S1720 - patent litigation reform. Issues Related to intellectual property practices in foreign countries and impact on US entities.
Antibiotic Development to Advance Patient Treatment Act. Issues related to oncology legislation, including medication affordability. Issues related to 21st Century Cures legislation.
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2014 · third_quarter · Q3
HR 3116 (MODDERN Cures Act) issues related to data exclusivity and patent rights for dormant therapies
Issues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures HR 3116 (MODDERN Cures Act) issues related to data exclusivity and patent rights for dormant therapies Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing programIssues related to pediatric medication access and impact of public guidelines on access Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number) Issues related to oncology legislation, including medication affordability Issues related to opiod use, diversion and DEA scheduling (no legislation) Issues related to transition of care from different care sites (no legislation) Issues related to drug safety and supply chain protections, including e-labeling (no bill number)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2014 · second_quarter · 2A
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program Issues related to pediatric medication access and impact of public guidelines on access Issues related to oncology legislation, including medication affordabilityIssues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2014 · second_quarter · 2A
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program Issues related to pediatric medication access and impact of public guidelines on access Issues related to oncology legislation, including medication affordabilityIssues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number)
S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2014 · second_quarter · Q2
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program Issues related to pediatric medication access and impact of public guidelines on access Issues related to oncology legislation, including medication affordabilityIssues related to 21st Century Cures legislation and role of incentives in advancement of treatments and cures Issues related to FDA and Biomedical Advanced Research Development Authority appropriations (no bill number) Medication adherence related legislation (no bill number)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2014 · first_quarter · Q1
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 3742 - Legislative proposals regarding the development and reimbursement of antibiotics Infant repiratory health issues - no legislation assigned
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2013 · fourth_quarter · 4A
H.R. 3204 and related legislative proposals - Drug safety and supply chain protections
H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2013 · fourth_quarter · 4A
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 3204 and related legislative proposals - Drug safety and supply chain protections H.R. 3742 - Legislative proposals regarding the development of antibiotics H.R. 2725, S. 1413 - FDA user feesFederal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration General discussions regarding patient adherence to prescribed medications regimens
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2013 · fourth_quarter · Q4
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform
H.R. 3204 and related legislative proposals - Drug safety and supply chain protections
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2013 · third_quarter · Q3
H.R. 1919, H.R. 3204, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs H.R. 1588, S. 740 - issues related to pharmaceutical rebates in Medicare Part D
H.R. 2582 - Patent user fees H.R. 2766 - patent reform H.R. 3116 - MODDERN Cures Act - legislation to provide patent incentives for the development of innovative diagnostic tests therapies
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2013 · second_quarter · Q2
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) as enacted in Pub. L. No. 112-144 development of antibiotics H.R. 1919, S.959, S.957 and related legislative proposals - Drug safety and supply chain protectionsFederal purchases under the Trade Agreements Act Federal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program
H.R.1919, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2013 · first_quarter · Q1
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) as enacted in Pub. L. No. 112-144 - issues related to the development of antibiotics S. 214, HR 845, S.Amd. 628 and related legislative proposals regarding possible restrictions on patent settlements Issues related to data exclusivity for patented biological products (No assigned legislation)
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) as enacted in Pub. L. No. 112-144 issues related to the development of antibiotics Issues related to drug safety and supply chain protections, including track and trace requirements (No assigned legislation)Issues related to federal purchases under the Trade Agreements Act Issues related to federal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to healthcare exchanges and essential health benefits Issues related to patient adherence to prescribed medication therapies (No assigned legislation) Issues related to oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program S. 264 (Excellence in Mental Health Act), S. 153 (Mental Health First Aid Act) issues related to mental health and pharmaceuticals
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · third_quarter · 3A
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates HR 5979 - issues related to proposed changes in Medicaid payments
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspectionsH.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs H.R. 6160 - issues related to drug safety, including tamper resistent packaging
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · fourth_quarter · Q4
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) as enacted in Pub. L. No. 112-144 issues related to the development of antibiotics Issues related to drug safety, supply chain, and facility inspections (No assigned legislation) Issues related to federal purchases under the Trade Agreements Act HR 6611 and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting Issues related to federal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to healthcare exchanges and essential health benefits
Issues related to drug safety, supply chain, and facility inspections (No assigned legislation) HR 6611 and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · second_quarter · 2A
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · third_quarter · Q3
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates HR 5979 - issues related to proposed changes in Medicaid payments
HR 2182, S1734, and S2187 (as passed in Pub. L. No. 112-144) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to 340B program amendments and implementation of statutory changes. HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to definition of essential health benefits and health insurance exchanges. HR 6160 - issues related to drug safety issues, including tamper resistent packaging HR 1513 - issues related to animal research HR 6502 - issues related to development of medicines for life-threatening illnesses HR 3497 - issues related to incentives for developing and improving diagnostic tests and related treatments HR 6272 - issues related to the expansion of clinical trial data banks and increase government reporting of same HR 6163 - issues related to incentives for increased research into pediatric treatments
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · first_quarter · 1A
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · second_quarter · Q2
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · first_quarter · 1A
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2012 · first_quarter · Q1
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · fourth_quarter · 4A
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · third_quarter · 3A
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · fourth_quarter · Q4
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · third_quarter · Q3
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP
2011 · third_quarter · Q3
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting Discussions regarding clinical trial issues HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including the Independent Payment Advisory Board HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
21st Century Cures/Innovation Proposal, Senate & House Prescription Drug Access, Senate & House Moonshot Initiative Chronic Care - Drug Adherence and Continuity of Care, House and Senate Value of Prescription Drugs, Senate & House Global Health/Non-Communicable Diseases in Africa - House & Senate
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
Medicare Part D coverage and reimbursement. Medicare Part D Low Income Subsidy. Legislative proposals to change Medicare Part D. Medicaid coverage. Medicare Part B proposed demonstration program. House and Senate.
21st Century Cures/Innovation Proposal, Senate & House Prescription Drug Access, Senate & House Moonshot Initiative Chronic Care - Drug Adherence and Continuity of Care, House and Senate Value of Prescription Drugs, Senate & House Global Health/Non-Communicable Diseases in Africa - House & Senate
Filing targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to drug safety and supply chain protections, including e-labeling (no bill number)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to low income beneficiaries and protected medication classes
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
S 1720 - patent litigation reform Issues related to intellectual property practices in foreign countries and impact on US entities
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 3204 and related legislative proposals - Drug safety and supply chain protections H.R. 3742 - Legislative proposals regarding the development of antibiotics H.R. 2725, S. 1413 - FDA user feesFederal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration General discussions regarding patient adherence to prescribed medications regimens
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 3204 and related legislative proposals - Drug safety and supply chain protections
H.R. 3309, S 1720, S 1013, S 1612 - patent litigation reform
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 3204 and related legislative proposals - Drug safety and supply chain protections H.R. 3742 - Legislative proposals regarding the development of antibiotics H.R. 2725, S. 1413 - FDA user feesFederal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration General discussions regarding patient adherence to prescribed medications regimens
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
Oversight and possible amendment or reform of federal 340B pharmaceutical purchasing program H.R. 1919, H.R. 3204, S.959, S.957 and related legislative proposals - Drug safety and supply chain protections Legislative proposals regarding the development of antibiotics (no assigned legislation) H.R. 2725, S. 1413 - FDA user feesH.R. 3116 - MODDERN Cures Act - legislation to provide patent incentives for the development of innovative diagnostic tests therapies Federal revenues, entitlement reform, and deficit reduction regarding ongoing fiscal talks and sequestration HR 2985 - regarding the development of new combination drugs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE, U.S. Trade Representative (USTR)
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - Medicare and Medicaid reform including issues related to adherence programs and non-interference Medicaid rebate formula (no assigned legislation)
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) as enacted in Pub. L. No. 112-144 development of antibiotics Strengthening incentives for developing and protecting intellectual property (no assigned legislation)S. 214, H.R.245, H.R.2024, S.1013, S.866, S.Amd. 628 and related legislative proposals regarding possible restrictions on patent settlements Data exclusivity for patented biological products (No assigned legislation)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D administration Issues related to the Medicaid rebate formula and applicability Issues related to possible imposition of rebates for Medicare Part B drugs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
HR 2182, S1734, and S2187 (as passed in Pub. L. No. 112-144) issues related to the development of antibiotics H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumerHR 1483 - issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to 340B program amendments and implementation of statutory changes. HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to definition of essential health benefits and health insurance exchanges. HR 6160 - issues related to drug safety issues, including tamper resistent packaging HR 1513 - issues related to animal research HR 6502 - issues related to development of medicines for life-threatening illnesses HR 3497 - issues related to incentives for developing and improving diagnostic tests and related treatments HR 6272 - issues related to the expansion of clinical trial data banks and increase government reporting of same HR 6163 - issues related to incentives for increased research into pediatric treatments
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) as enacted in Pub. L. No. 112-144 issues related to the development of antibiotics S. 27 and related legislative proposals regarding possible restrictions on patent settlements HR 6353 and related legislative proposals regarding possible changes to tax law regarding intellectual property profits H.R. 6621 and related legislative proposals regarding technical fixes in patent reform
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D administration Issues related to the Medicaid rebate formula
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs S. Amend. t.2107 and related legislative proposals regarding prescription drug importation
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
H.R. 3026, S. 1882 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 issues related to drug safety, supply chain, and facility inspections H.R. 2245, S.296, H.R. 3839 (Prescribing Access to Lifesaving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages, including notifications and public reporting H.R. 3668 issues related to increased penalties for counterfeiting drugs H.R. 6160 - issues related to drug safety, including tamper resistent packaging
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
H.R. 5651, S. 3187 (Prescription Drug User Fee Act (PFUFA)) FDA funding issues, including issues such as user fees and future appropriations HR 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) and related legislation related to issues of pediatric exclusivity S. 2295, H.R. 4384 and related legislation regarding pharmaceutical labeling changes
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements. HR 2190, S 1206 and related legislative proposals regarding changes/scope of Medicare Part D rebates
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
H.R. 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) issues related to Medicare and Medicaid reform, including possible changes to Part D and changes to Medicaid price reporting requirements H.R. 2245, S. 296, H.R. 3839(Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting H.R. 2182, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics H.R. 452 IPAB (Independent Payment Advisory Board) Medicare Decisions Accountability Act of 2011 S.1882, H.R. 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer; HR 1483 - issues related to drug safety, supply chain, and facility inspections HR 3468 - issues related to increased penalties for counterfeiting drugs Discussions regarding use of psychotropic drugs by children in foster care HR 1254 (Synthetic Drug Control Act) - issues related to propsed controlled substance amendments S 2113 (Transforming Regulatory Environment to Accelerate Access to Treatments Act) - issues related to acceleration of innovation and approvals of medical treatments
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
H.R. 2128, S. 1734 GAIN (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics Issues related to US position on intellectual property matters in Canada
FDA funding issues, including issues such as user fees and possible future appropriations that are likely to be incorporated into the Prescription Drug User Fee Act (PDUFA) (no bill number yet) H.R. 4274 (PREA Authorization Act of 2012, Best Pharmaceuticals for Children Act and Pediatric Research Equity Act of 2003) - issues related to pediatric exclusivity and related issues to be incorporated into PDUFA legislation
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program
HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including possible changes to Part D rebates HR 2245, S 296 (Preserving Access to Life-Saving Medications Act of 2011) and related legislative proposals regarding issues surrounding potential drug shortages including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 2674 and related legislative proposals regarding expansion of 340B health care program HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics HR 1254 (Synthetic Drug Control Act) - issues related to proposed controlled substance amendments HR 3206 - issues related to FDA appointments to advisory panels and conflicts of interest HR 1483 - issues related to drug safety, supply chain, and facility inspections
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center, comparative effectiveness research, and accountable care organizations HR 3342, S 1356 - issues related to utilization of generic drugs in Medicaid program
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
HR 1483, S.1584, S. Amdt. 769 and related legislative proposals regarding prescription drug importation and safety issues HR 2245, S.296 (Preserving Access to Life Saving Medications Act) and related legislative proposals regarding issues surrounding potential drug shortages, including notification and public reporting HR 3026 and related legislative proposals regarding establishment/implementation of pharmaceutical pedigrees and tracking/tracing of pharmaceuticals from manufacturer to consumer HR 1483 - issues related to drug safety, supply chain, and facility inspections S 1946 (Foreign Manufacturers Legal Accountability Act) - issues related to registration of foreign manufacturers
HR 2182 (Generating Antibiotic Incentives Now Act of 2011) - issues related to the development of antibiotics S. 27 (Preserve Access to Affordable Generics Act) - Legislative proposals surrounding patent reform and intellectual property issues, including patent settlements Issues related to US position on intellectual property protections offered by US in international trade treaty
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
HR 2190, S.1206 and related legislation proposals regarding changes/scope of Medicare Part D Rebates HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to Medicare and Medicaid reform, including issues related to Medicaid price reporting, rebate calculation, and expansion of eligible utilization HR 3590, S 1790 (as enacted into PL 111-148 and PL 111-152) - issues related to health care reform, including the CMS Innovation Center and comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office